Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.
about
Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and childrenInterventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and childrenEfficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.Practice guidelines for lipid-based amphotericin B in stem cell transplant recipients.Lipid-based amphotericin B for the treatment of fungal infections.Amphotericin B in lipid emulsion: stability, compatibility, and in vitro antifungal activity.Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patientsEfficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephrAmphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.Serum pharmacology of amphotericin B applied in lipid emulsions.Reduction in the nephrotoxicity of amphotericin B when administered in 20% intralipidCyclic-nucleotide signalling in protozoa.Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity.Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion.Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis.Efficacy and safety of amphotericin B formulations: a network meta-analysis and a multicriteria decision analysis.Amphotericin B toxicity reduced by administration in fat emulsion.Rapid infusion of amphotericin B in dextrose.Intralipid in prophylaxis of amphotericin B nephrotoxicity.Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia.In search of the amazing technicolour dream coat for amphotericin B.Amphotericin B is incompatible with lipid emulsions.
P2860
Q24236693-43E3B0D1-E8FF-4972-A5BA-6F578AE76F17Q24244997-B9F8BB18-06F6-42AF-936C-41BFACC1A7E2Q30240770-87824C3A-05AE-4121-8066-7395E2559C27Q32052950-6869C0BB-C26D-48BF-8239-E81B540B58DBQ33604227-43F6C751-0247-45B1-97BA-B04EAB3B7CD8Q33692176-80359D28-27C4-4C65-BD26-D35102276012Q33824631-367B938F-B1E6-448F-A413-C9912E961262Q33976955-214865D9-3E2B-44C7-B5AB-5ADDF91F36EEQ33978188-82B45AFA-7734-4463-A83B-DB2C8BBD70A7Q34294886-CB502D21-FDF2-4A8C-8FFC-2CFA5FDA2CE4Q35122944-F70CD586-07F9-49CB-80B5-92375B0EA7BAQ35134565-F0ABF14A-DDE3-4AFD-ADE6-D20EE49E69D9Q35891310-4FC6EE33-2321-46C8-B07D-B8FF3D8FF0F1Q37827560-E2B9CAB5-CA95-422B-81DC-F3992135C850Q38077678-6BF88A1B-FB86-4EC6-A5A4-AC273B1A5647Q39470922-9B1DE11F-87E4-4D54-83F6-E6410A42B6D2Q39476255-D8621155-0168-40BA-9F36-8BB42B9F3D6CQ40043040-8507D2FE-4B8C-471E-9011-2299A24633B5Q40471190-4377E215-309A-4575-B7FB-24165F02BAA6Q40471207-177446E5-46FC-4F0F-B719-97142903BC53Q40582560-8C54F091-615C-4080-B06C-907C5C109934Q40677144-AE49E4C1-A0F4-4A1F-ADD1-F18CF1B71CFBQ42544559-EC5537C7-6CB6-498A-AFF6-EB6ED1BC6E31Q54122029-45F1C060-E9EB-4108-AEF6-54FC97DF0C5F
P2860
Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Trial of glucose versus fat em ...... ted patients with candidiasis.
@en
type
label
Trial of glucose versus fat em ...... ted patients with candidiasis.
@en
prefLabel
Trial of glucose versus fat em ...... ted patients with candidiasis.
@en
P2093
P2860
P356
P1433
P1476
Trial of glucose versus fat em ...... ted patients with candidiasis.
@en
P2093
Charlier N
Chavanet PY
Kisterman JP
P2860
P304
P356
10.1136/BMJ.305.6859.921
P407
P577
1992-10-01T00:00:00Z